Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

Alfonso Quintás-Cardama, Hagop Kantarjian, Zeev Estrov, Gautam Borthakur, Jorge Cortes, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Approximately half of the patients with myelofibrosis (MF) carry mutant JAK2 V617F proteins. JAK2 V617F has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription. We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60mg every other day for three weeks per month in 22 patients with intermediate or high risk MF. Eight (36%) patients experienced clinical benefit, with 6 (27%) experiencing reductions in splenomegaly (median 3cm, range 1-4cm). According to International Working Group criteria, 2 (9%) patients had clinical improvement (anemia response in both cases). The most frequent side effect associated to pracinostat therapy was fatigue, which occurred in 20 (91%) patients (grade 2 in 3 patients). Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13%, 0%, and 21%, respectively. Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy. In conclusion, pracinostat at the dose tested is reasonably tolerated and has modest activity in patients with MF.

Original languageEnglish (US)
Pages (from-to)1124-1127
Number of pages4
JournalLeukemia Research
Volume36
Issue number9
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Histone Deacetylase Inhibitors
Therapeutics
Anemia
SB939 compound
Splenomegaly
Neutropenia
Thrombocytopenia
Histones
Fatigue

Keywords

  • Histone deacetylase inhibitor
  • JAK2
  • Myelofibrosis
  • Pracinostat
  • SB939

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Quintás-Cardama, A., Kantarjian, H., Estrov, Z., Borthakur, G., Cortes, J., & Verstovsek, S. (2012). Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leukemia Research, 36(9), 1124-1127. https://doi.org/10.1016/j.leukres.2012.03.003

Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. / Quintás-Cardama, Alfonso; Kantarjian, Hagop; Estrov, Zeev; Borthakur, Gautam; Cortes, Jorge; Verstovsek, Srdan.

In: Leukemia Research, Vol. 36, No. 9, 01.09.2012, p. 1124-1127.

Research output: Contribution to journalArticle

Quintás-Cardama, A, Kantarjian, H, Estrov, Z, Borthakur, G, Cortes, J & Verstovsek, S 2012, 'Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis', Leukemia Research, vol. 36, no. 9, pp. 1124-1127. https://doi.org/10.1016/j.leukres.2012.03.003
Quintás-Cardama, Alfonso ; Kantarjian, Hagop ; Estrov, Zeev ; Borthakur, Gautam ; Cortes, Jorge ; Verstovsek, Srdan. / Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. In: Leukemia Research. 2012 ; Vol. 36, No. 9. pp. 1124-1127.
@article{b5a0a3c41aa642ecb0726048e4015618,
title = "Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis",
abstract = "Approximately half of the patients with myelofibrosis (MF) carry mutant JAK2 V617F proteins. JAK2 V617F has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription. We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60mg every other day for three weeks per month in 22 patients with intermediate or high risk MF. Eight (36{\%}) patients experienced clinical benefit, with 6 (27{\%}) experiencing reductions in splenomegaly (median 3cm, range 1-4cm). According to International Working Group criteria, 2 (9{\%}) patients had clinical improvement (anemia response in both cases). The most frequent side effect associated to pracinostat therapy was fatigue, which occurred in 20 (91{\%}) patients (grade 2 in 3 patients). Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13{\%}, 0{\%}, and 21{\%}, respectively. Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy. In conclusion, pracinostat at the dose tested is reasonably tolerated and has modest activity in patients with MF.",
keywords = "Histone deacetylase inhibitor, JAK2, Myelofibrosis, Pracinostat, SB939",
author = "Alfonso Quint{\'a}s-Cardama and Hagop Kantarjian and Zeev Estrov and Gautam Borthakur and Jorge Cortes and Srdan Verstovsek",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.leukres.2012.03.003",
language = "English (US)",
volume = "36",
pages = "1124--1127",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis

AU - Quintás-Cardama, Alfonso

AU - Kantarjian, Hagop

AU - Estrov, Zeev

AU - Borthakur, Gautam

AU - Cortes, Jorge

AU - Verstovsek, Srdan

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Approximately half of the patients with myelofibrosis (MF) carry mutant JAK2 V617F proteins. JAK2 V617F has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription. We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60mg every other day for three weeks per month in 22 patients with intermediate or high risk MF. Eight (36%) patients experienced clinical benefit, with 6 (27%) experiencing reductions in splenomegaly (median 3cm, range 1-4cm). According to International Working Group criteria, 2 (9%) patients had clinical improvement (anemia response in both cases). The most frequent side effect associated to pracinostat therapy was fatigue, which occurred in 20 (91%) patients (grade 2 in 3 patients). Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13%, 0%, and 21%, respectively. Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy. In conclusion, pracinostat at the dose tested is reasonably tolerated and has modest activity in patients with MF.

AB - Approximately half of the patients with myelofibrosis (MF) carry mutant JAK2 V617F proteins. JAK2 V617F has been recently shown to translocate to the nucleus and modify specific histones, thus regulating transcription. We report on a phase II study testing the activity and tolerability of the histone deacetylase inhibitor pracinostat given at 60mg every other day for three weeks per month in 22 patients with intermediate or high risk MF. Eight (36%) patients experienced clinical benefit, with 6 (27%) experiencing reductions in splenomegaly (median 3cm, range 1-4cm). According to International Working Group criteria, 2 (9%) patients had clinical improvement (anemia response in both cases). The most frequent side effect associated to pracinostat therapy was fatigue, which occurred in 20 (91%) patients (grade 2 in 3 patients). Grade 3-4 neutropenia, anemia, and thrombocytopenia occurred in 13%, 0%, and 21%, respectively. Twenty-one patients permanently discontinued pracinostat, mainly due to lack of efficacy. In conclusion, pracinostat at the dose tested is reasonably tolerated and has modest activity in patients with MF.

KW - Histone deacetylase inhibitor

KW - JAK2

KW - Myelofibrosis

KW - Pracinostat

KW - SB939

UR - http://www.scopus.com/inward/record.url?scp=84864008019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864008019&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.03.003

DO - 10.1016/j.leukres.2012.03.003

M3 - Article

C2 - 22475363

AN - SCOPUS:84864008019

VL - 36

SP - 1124

EP - 1127

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -